These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 21664161

  • 1. Growth hormone treatment for two years is safe and effective in adults with Prader-Willi syndrome.
    Sode-Carlsen R, Farholt S, Rabben KF, Bollerslev J, Schreiner T, Jurik AG, Frystyk J, Christiansen JS, Höybye C.
    Growth Horm IGF Res; 2011 Aug; 21(4):185-90. PubMed ID: 21664161
    [Abstract] [Full Text] [Related]

  • 2. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
    Festen DA, de Lind van Wijngaarden R, van Eekelen M, Otten BJ, Wit JM, Duivenvoorden HJ, Hokken-Koelega AC.
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884
    [Abstract] [Full Text] [Related]

  • 3. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome.
    Myers SE, Carrel AL, Whitman BY, Allen DB.
    J Pediatr; 2000 Jul; 137(1):42-9. PubMed ID: 10891820
    [Abstract] [Full Text] [Related]

  • 4. Five-years growth hormone (GH) treatment in adults with Prader-Willi syndrome.
    Höybye C.
    Acta Paediatr; 2007 Mar; 96(3):410-3. PubMed ID: 17407467
    [Abstract] [Full Text] [Related]

  • 5. Body composition, endocrine and metabolic profiles in adults with Prader-Willi syndrome.
    Sode-Carlsen R, Farholt S, Rabben KF, Bollerslev J, Schreiner T, Jurik AG, Christiansen JS, Höybye C.
    Growth Horm IGF Res; 2010 Jun; 20(3):179-84. PubMed ID: 20199883
    [Abstract] [Full Text] [Related]

  • 6. Growth hormone induced lipolysis during short- and long-term administration in adult Prader-Willi patients.
    Höybye C, Hilding A, Marcus C, Thorén M.
    Growth Horm IGF Res; 2005 Dec; 15(6):411-5. PubMed ID: 16230042
    [Abstract] [Full Text] [Related]

  • 7. One year of growth hormone treatment in adults with Prader-Willi syndrome improves body composition: results from a randomized, placebo-controlled study.
    Sode-Carlsen R, Farholt S, Rabben KF, Bollerslev J, Schreiner T, Jurik AG, Christiansen JS, Höybye C.
    J Clin Endocrinol Metab; 2010 Nov; 95(11):4943-50. PubMed ID: 20702523
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome.
    de Lind van Wijngaarden RF, Siemensma EP, Festen DA, Otten BJ, van Mil EG, Rotteveel J, Odink RJ, Bindels-de Heus GC, van Leeuwen M, Haring DA, Bocca G, Houdijk EC, Hoorweg-Nijman JJ, Vreuls RC, Jira PE, van Trotsenburg AS, Bakker B, Schroor EJ, Pilon JW, Wit JM, Drop SL, Hokken-Koelega AC.
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4205-15. PubMed ID: 19837938
    [Abstract] [Full Text] [Related]

  • 9. Growth hormone treatment completely normalizes adult height and improves body composition in Prader-Willi syndrome: experience from KIGS (Pfizer International Growth Database).
    Lindgren AC, Lindberg A.
    Horm Res; 2008 Nov; 70(3):182-7. PubMed ID: 18663319
    [Abstract] [Full Text] [Related]

  • 10. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome.
    Carrel AL, Moerchen V, Myers SE, Bekx MT, Whitman BY, Allen DB.
    J Pediatr; 2004 Dec; 145(6):744-9. PubMed ID: 15580194
    [Abstract] [Full Text] [Related]

  • 11. Growth hormone treatment of adults with Prader-Willi syndrome and growth hormone deficiency improves lean body mass, fractional body fat, and serum triiodothyronine without glucose impairment: results from the United States multicenter trial.
    Mogul HR, Lee PD, Whitman BY, Zipf WB, Frey M, Myers S, Cahan M, Pinyerd B, Southren AL.
    J Clin Endocrinol Metab; 2008 Apr; 93(4):1238-45. PubMed ID: 18211968
    [Abstract] [Full Text] [Related]

  • 12. Growth hormone treatment in adults with Prader-Willi syndrome: the Scandinavian study.
    Sode-Carlsen R, Farholt S, Rabben KF, Bollerslev J, Schreiner T, Jurik AG, Christiansen JS, Höybye C.
    Endocrine; 2012 Apr; 41(2):191-9. PubMed ID: 22081257
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study.
    Hansen TB, Gram J, Jensen PB, Kristiansen JH, Ekelund B, Christiansen JS, Pedersen FB.
    Clin Nephrol; 2000 Feb; 53(2):99-107. PubMed ID: 10711411
    [Abstract] [Full Text] [Related]

  • 16. Body composition during GH treatment in Prader-Labhardt-Willi syndrome.
    Bosio L, Beccaria L, Benzi F, Sanzari A, Chiumello G.
    J Pediatr Endocrinol Metab; 1999 Apr; 12 Suppl 1():351-3. PubMed ID: 10698601
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Growth hormone treatment improves body composition in adults with Prader-Willi syndrome.
    Höybye C, Hilding A, Jacobsson H, Thorén M.
    Clin Endocrinol (Oxf); 2003 May; 58(5):653-61. PubMed ID: 12699450
    [Abstract] [Full Text] [Related]

  • 19. Effects of recombinant human growth hormone therapy in adults with Prader-Willi syndrome: a meta-analysis.
    Sanchez-Ortiga R, Klibanski A, Tritos NA.
    Clin Endocrinol (Oxf); 2012 Jul; 77(1):86-93. PubMed ID: 22117629
    [Abstract] [Full Text] [Related]

  • 20. Two years of growth hormone treatment in adults with Prader-Willi syndrome do not improve the low BMD.
    Jørgensen AP, Ueland T, Sode-Carlsen R, Schreiner T, Rabben KF, Farholt S, Høybye C, Christiansen JS, Bollerslev J.
    J Clin Endocrinol Metab; 2013 Apr; 98(4):E753-60. PubMed ID: 23436915
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.